NASDAQ: BIIBBiogen Revenue
Biogen revenue was $10.07B for the trailing 12 months ending Sep 30, 2025, with -1.1% growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $2.5B, down 4.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BIIB annual revenue was $9.7B, with -1.6% growth year-over-year.
BIIB past revenue growth
How has BIIB's revenue growth performed historically?
Company
4.77%
Industry
17.83%
Market
20.49%
BIIB's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
BIIB's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
BIIB's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
BIIB revenue history
Current Revenue
$10.1B
Current Earnings
$1.6B
Current Profit Margin
16%
BIIB's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance
Be the first to know when BIIB announces revenue.
BIIB Revenue History By Year
| BIIB Yearly Revenue | BIIB Revenue | BIIB Change | BIIB Revenue Growth |
|---|---|---|---|
| 2024-12-31 | $9.68B | -$159.70M | -1.62% |
| 2023-12-31 | $9.84B | -$337.80M | -3.32% |
| 2022-12-31 | $10.17B | -$808.30M | -7.36% |
| 2021-12-31 | $10.98B | -$2.46B | -18.32% |
| 2020-12-31 | $13.44B | -$933.30M | -6.49% |
| 2019-12-31 | $14.38B | $925.00M | +6.88% |
| 2018-12-31 | $13.45B | $1.18B | +9.61% |
| 2017-12-31 | $12.27B | $825.10M | +7.21% |
| 2016-12-31 | $11.45B | $685.00M | +6.36% |
| 2015-12-31 | $10.76B | $1.06B | +10.93% |
| 2014-12-31 | $9.70B | $2.77B | +39.97% |
| 2013-12-31 | $6.93B | $1.42B | +25.66% |
| 2012-12-31 | $5.52B | $467.83M | +9.27% |
| 2011-12-31 | $5.05B | $332.21M | +7.04% |
| 2010-12-31 | $4.72B | $339.08M | +7.75% |
| 2009-12-31 | $4.38B | $279.84M | +6.83% |
| 2008-12-31 | $4.10B | $925.89M | +29.19% |
| 2007-12-31 | $3.17B | $488.57M | +18.21% |
| 2006-12-31 | $2.68B | $260.55M | +10.76% |
| 2005-12-31 | $2.42B | $210.94M | +9.54% |
| 2004-12-31 | $2.21B | $1.53B | +225.62% |
| 2003-12-31 | $679.18M | $274.96M | +68.02% |
| 2002-12-31 | $404.22M | $131.55M | +48.24% |
| 2001-12-31 | $272.68M | $118.00M | +76.28% |
| 2000-12-31 | $154.68M | $36.68M | +31.08% |
| 1999-12-31 | $118.00M | $31.04M | +35.70% |
| 1998-12-31 | $86.96M | $42.35M | +94.95% |
| 1997-12-31 | $44.61M | $14.60M | +48.64% |
| 1996-12-31 | $30.01M | $6.37M | +26.96% |
| 1995-12-31 | $23.64M | $16.19M | +217.56% |
| 1994-12-31 | $7.44M | N/A | N/A |
Biogen Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.